Approval · Notice of Compliance 27833 · 2022
PENTASA: Notice of Compliance 27833
Issued March 25, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27833
- Date
- March 25, 2022
- Company
- Ferring Inc.North York, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) in response to an Advisement Letter, and to update the PM to the 2020 Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PENTASA | Not yet assigned | — |
Medicinal ingredients
- MESALAZINE 500 MG per TAB
- MESALAZINE 1 G per TAB
- MESALAZINE 1 G per SUP
- MESALAZINE 1 G per 100ML
- MESALAZINE 4 G per 100ML